Harpreet Singh, MD @harpreet_md Twitter profile

Pinned Tweet

Harpreet Singh, MD

3 months

🥼First ASCO as Chief Medical Officer of Precision for Medicine 🧬Loved hearing about so much great science and diving right in help biotech bring more promising therapies to patients! #ASCO24 #CMO #biotech @Precision4Med

0

7

101

Last Seen Profiles

@dethesle81918

@LovorAl

@beafandraw

@Paparadis

@TMFederation

@DILU6c53nDl4aKK

@minaaaaaachan11

@robson_smj

@YBuriet

@u18atlantics

@intanhwang_

@sowa_jim

@ina_site

@stw46

@TanzaniaInsight

@nornXP

@hannerno1

@vgytfx1

@CircusCharliiie

@oljsjsjjddn2

@JFTremblay_LP

@Chloe_Kerrie95

@sandra_slut2

@bokeplokalmalam

@Astr4_fn

@OliRandom

@durandeau6

@Sasakumaru

@mg_hina

@LoverP1zza

@saya_1317

@sonyayori

@_Myrcene

@ChorkaSCTs

@TaaPooMaa

@whsbarronsbball

Harpreet Singh, MD

@harpreet_md

4 years

When I leave work, I’m a wife, daughter, and stepmom to 3 Black men. When any of them leave the house, we say “love you, stay safe” - it’s part of our lives. I hope that we can all continue this work, checking our biases. For my family, and for my daughter Norah. #BLM

9

24

358

Harpreet Singh, MD

@harpreet_md

3 years

🪔 Happy Diwali from ours to yours 🪔

8

6

272

Harpreet Singh, MD

@harpreet_md

3 years

FDA pushes cancer trials to include more elderly people | Science | AAAS

FDA pushes cancer trials to include more elderly people

New guidance aims to improve understanding of drug safety, effectiveness in older adults

www.science.org

7

60

249

Harpreet Singh, MD

@harpreet_md

5 years

Patient advocacy at its finest. Beverly Canin asking how we can empower more oncologists to offer clinical trials to ALL patients. Leaning from every patient... #ASCO19 @ASCO

3

36

166

Harpreet Singh, MD

@harpreet_md

10 months

Happy Diwali 🪔 Wishing you light, love, peace and prosperity this season ✨

9

2

135

Harpreet Singh, MD

@harpreet_md

4 months

I am thrilled to join Precision for Medicine as Chief Medical Officer! Looking forward to leveraging my deep medical knowledge and regulatory expertise to drive novel treatments forward for patients with cancer and rare diseases. ⚕️🥼🧬

Precision for Medicine

@Precision4Med

4 months

Harpreet Singh, MD has joined Precision as Chief Medical Officer after over a decade of experience at FDA & National Cancer Institute. Dr. Singh oversaw multiple oncology & rare disease programs at the FDA. Her insights will be invaluable to our clients.

0

3

43

5

128

Harpreet Singh, MD

@harpreet_md

4 years

This is the 8th approval for NSCLC in the year 2020!

FDA Oncology

@FDAOncology

4 years

On September 4, 2020, FDA granted accelerated approval to pralsetinib (GAVRETO, Blueprint Medicines Corporation) for adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test.

0

8

28

3

18

108

Harpreet Singh, MD

@harpreet_md

4 years

Today, FDA approved selpercatinib for patients with: ✅ RET-fusion NSCLC ✅ RET-mutant MTC ✅ RET-fusion thyroid cancer ✳️ all indications line-agnostic 3️⃣ months ahead of FDA goal date . @FDAOncology #lcsm #thycsm

FDA Oncology

@FDAOncology

4 years

FDA approved Retevmo (selpercatinib) to treat non-small cell lung cancer and thyroid cancers in patients whose tumors have a RET gene mutation or fusion. Retevmo is the 1st therapy approved specifically for cancer with RET gene alterations. #lcsm #thycsm

1

51

87

6

30

102

Harpreet Singh, MD

@harpreet_md

3 years

Thrilled to see this in print. Thank you @theNASEM @bertagnollimm @FDAOncology for your commitment to our Older Adults with Cancer — Addressing Gaps in Evidence | NEJM

Treatment of Older Adults with Cancer — Addressing Gaps in Evidence | NEJM

Older adults with cancer are underrepresented in clinical research. Because of insufficient data, such patients and their physicians must make life-altering treatment decisions without adequate evi...

www.nejm.org

4

26

94

Harpreet Singh, MD

@harpreet_md

4 years

✨Happy 2nd birthday to our sweet Norah Grace. ✨

5

1

83

Harpreet Singh, MD

@harpreet_md

3 years

Wonderful news today for patients and kuddos to the Thoracic team at @FDAOncology for expediting this critical approval.

U.S. FDA

@US_FDA

3 years

Today, FDA approved the first treatment for adult patients with non-small cell lung cancer whose tumors have a specific type of genetic mutation called KRAS G12C and who have received at least one prior systemic therapy.

7

104

177

2

7

81

Harpreet Singh, MD

@harpreet_md

5 years

Thrilled to join my friends and colleagues @ASCO but leaving these smiles behind doesn’t get easier 💗 see you soon Chicago ✈️ #ASCO19

8

1

75

Harpreet Singh, MD

@harpreet_md

4 years

Thanks ⁦ @nytimes ⁩ for interviewing me for this piece. Eligibility criteria for COVID-19 trials should be closely examined, with concerted efforts to enroll older adults. #COVID19

Older Adults May Be Left Out of Some Covid-19 Trials (Published 2020)

The coronavirus disproportionately affects seniors, but they may not be included in important clinical trials for vaccines and treatments.

www.nytimes.com

1

18

73

Harpreet Singh, MD

@harpreet_md

4 years

This is the 9th approval for patients with NSCLC in 2020, and importantly was reviewed with multiple countries under @FDAOncology Project ORBIS 🌎

FDA Oncology

@FDAOncology

4 years

FDA approved osimertinib (TAGRISSO, AstraZeneca) for adjuvant therapy after tumor resection in patients with non-small cell lung cancer whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations as detected by an FDA-approved test. #lcsm

0

50

110

1

9

72

Harpreet Singh, MD

@harpreet_md

5 years

✨Thankful to ASCO for providing childcare at this years meeting. While this year my wonderfully supportive husband will be holding down the fort, as a new mom I certainly applaud ASCO for recognizing and addressing this critical issue. ✨ @ASCO

0

10

70

Harpreet Singh, MD

@harpreet_md

4 years

Today, FDA approved: ✅ Atezolizumab for 1L NSCLC with high PD-L1 expression ✅ q2, q3, and q4 dosing schedules approved #lcsm

FDA Oncology

@FDAOncology

4 years

FDA approved atezolizumab (TECENTRIQ®, Genentech) for 1st-line treatment of metastatic NSCLC with high PD-L1 expression with no EGFR or ALK genomic tumor aberrations. #lcsm

0

24

40

1

30

65

Harpreet Singh, MD

@harpreet_md

4 years

#OCEWorks4U . @FDAOncology I love my day to day work and know that it has a direct impact on patients lives. That’s what keeps me motivated. Every day, my work in cancer is for you! ✨

FDA Oncology

@FDAOncology

4 years

OCE continues to support the cancer community during COVID-19. Meet Dr. Harpreet Singh @harpreet_md , Director, Division of Oncology 2 in FDA’s Office of Oncologic Diseases. #OCEWorks4U .

0

3

28

3

2

64

Harpreet Singh, MD

@harpreet_md

4 years

Today, FDA approved nivolumab + ipilimumab & 2 cycles of chemotherapy for metastatic NSCLC based on the 9LA study. ✅ Part of OCE’s Project ORBIS ✅ reviewed with HC, TGA, HSA 2️⃣ months ahead of FDA goal . @FDAOncology

FDA Oncology

@FDAOncology

4 years

Today FDA approved nivolumab + ipilimumab & 2 cycles of platinum-doublet chemotherapy as 1st-line treatment for patients with metastatic/recurrent NSCLC with no EGFR or ALK genomic tumor aberrations. #lcsm nivolumab: ipilimumab:

1

38

62

5

19

64

Harpreet Singh, MD

@harpreet_md

5 years

FDA encourages enrollment of older adults with cancer on clinical trials. See the draft guidance 👇🏽 @FDAOncology @myCARG

Media Affairs

@FDAMedia

5 years

Today the FDA issued draft guidance to provide recommendations for the inclusion of older adult patients, aged 65 years and older, in the clinical trials of drugs for the treatment of cancer.

0

17

14

4

17

63

Harpreet Singh, MD

@harpreet_md

5 months

Thrilled to join my FDA colleagues at #AACR24 - join us at one of our @FDAOncology sessions!

0

1

62

Harpreet Singh, MD

@harpreet_md

1 year

I had a wonderful time at ASCO but had to make it back for a very important ballet recital! 🩰🫶🏽🩰

2

62

Harpreet Singh, MD

@harpreet_md

4 years

Dr. Harpreet Singh Discusses the Conduct of FDA Clinical Trials During the COVID-19 Pandemic

1

10

61

Harpreet Singh, MD

@harpreet_md

4 years

Vote 🗳 ~ no lines today in Washington DC 🇺🇸

2

0

56

Harpreet Singh, MD

@harpreet_md

5 years

Happy 1st birthday to my Norah Grace 💗✨

5

0

56

Harpreet Singh, MD

@harpreet_md

2 years

✨❤️Happy 6 months to my sweet baby Noah ❤️6️⃣✨

1

0

55

Harpreet Singh, MD

@harpreet_md

5 years

Today was tough. In grieving Arti I recalled that for the last 3 years, we have shared a stage at a ASCO as mentor and mentee - and as friends. So I channeled my grief into some retail therapy, and gave to her endowed YIA fund 🙏🏽 #DrHurriasLight #ASC019 #GeriOnc @myCARG @ASCO

1

10

54

Harpreet Singh, MD

@harpreet_md

4 months

Making an impact while working with visionary leaders - that’s a win win! @FDAOncology

0

3

50

Harpreet Singh, MD

@harpreet_md

3 years

Published today! 2 Gains, 2 Losses - Immunotherapy in SCLC | Lung Cancer | JAMA Oncology | JAMA Network

Immunotherapy for Patients With Small-Cell Lung Cancer

This Viewpoint discusses trials of immunotherapy for the treatment of small-cell lung cancer.

jamanetwork.com

1

10

49

Harpreet Singh, MD

@harpreet_md

4 years

New treatment option for patients with mesothelioma, approved 5 months ahead of goal date, utilizing innovative OCE regulatory tools, such as RTOR, Assessment Aid, and ORBIS - impacting patients worldwide.

FDA Oncology

@FDAOncology

4 years

Today the FDA approved the combination of nivolumab plus ipilimumab as first-line treatment for adult patients with unresectable malignant pleural #mesothelioma

0

31

64

1

10

49

Harpreet Singh, MD

@harpreet_md

4 years

. @FDAOncology discussed emerging topics in lung cancer with thoracic oncologists and advocates. Missing @drgandara - was a great afternoon! #LCSM

1

10

48

Harpreet Singh, MD

@harpreet_md

5 years

Wonderful efforts underway to continue to broaden eligibility criteria for cancer clinical trials. @FDAOncology @ASCO

Anna Jinkerson

@AnnaJinkerson

5 years

Packed house early on Friday morning here at @asco with cancer care and research professionals from all over the country to discuss clinical trial eligibility criteria cc: @FDAOncology @CancerResrch

3

8

59

2

7

46

Harpreet Singh, MD

@harpreet_md

6 years

We recently published this analysis on older adults with lung CA. Contributing to our knowledge base for treating older adults with cancer. Remembering Arti as we continue our work.

FDA Oncology

@FDAOncology

6 years

#FDAOncology analysis of survival in older adults w/ metastatic NSCLC in PD-1/PD-L1 trials: Pts ≥65 including those ≥75 yrs seem to derive similar survival benefits from PD-1/PD-L1 blocking antibodies as those <65

1

18

27

2

12

43

Harpreet Singh, MD

@harpreet_md

5 years

Thrilled to share our JCO pub on outcomes of older women treated with CDK4/6 inhibitors🙌🏽 ⁦ @LynnHowie1 ⁩

3

13

44

Harpreet Singh, MD

@harpreet_md

7 months

OCE past and present ! Amy McKee, Gideon Blumenthal, Rick Pazdur, Julia Beaver, Geoff Kim, Jenny Gao at the FOCR and Prevision Policy BioPharma Congress ✨ @FDAOncology reunion

1

6

39

Harpreet Singh, MD

@harpreet_md

5 months

Kudos to @lobo_goulart for moderating a spirited panel on perioperative trials in solid tumors. How much is enough ? ✨🩺 @FDAOncology #AACR24

1

4

41

Harpreet Singh, MD

@harpreet_md

11 months

Thank you to the National Academies for this wonderful opportunity to discuss the value of public-private partnerships, mutually advancing cancer care and drug development. #fdaoncology #oce

0

4

40

Harpreet Singh, MD

@harpreet_md

5 years

Honored with the opportunity to open @IASLC Targeted Therapies conference! #ttlc20 @FDAOncology

Lauren Meehan Machos, MPH

@LaurenMachos

5 years

Great presentation from @harpreet_md and @FDAOncology on drug approvals for NSCLC including #targetedtherapy and #immunotherapy #ttlc20 17 drug approvals since 2011

0

9

0

3

38

Harpreet Singh, MD

@harpreet_md

3 years

@RABuckle My daughter loves loves loves DocMcStuffuns - such a great contribution to kids programming. We need more ❤️✨

0

36

Harpreet Singh, MD

@harpreet_md

5 years

Thanks @JCO_ASCO for promoting our efforts to improve that evidence base to treat older adults with cancer. Today is also a day in which Arti is being remembered in an NCI webinar, led by @WilliamDale_MD and @rochgerionc I know she would be thrilled to see this in print✨

Journal of Clinical Oncology

@JCO_ASCO

5 years

Outcomes of older women with HR+/HER2- metastatic breast cancer treated with CDK4/6 inhibitor and aromatase inhibitor #bcsm @LynnHowie1 @harpreet_md @FDAOncology

0

13

31

2

14

37

Harpreet Singh, MD

@harpreet_md

2 years

Thrilled to see @TerriConneran at @IASLC conference! Such a fierce patient advocate for all, especially @KRASKickers ! ❤️. @FDAOncology

2

38

Harpreet Singh, MD

@harpreet_md

6 years

Posting in loving memory of Arti who remains on my mind and in my heart. This was taken about a year ago at our first ASCO-FDA public workshop dedicated to Geriatric Oncology. Our work continues...

1

9

35

Harpreet Singh, MD

@harpreet_md

6 years

Extremely important that our clinical trials reflect the population which will ultimately be treated with the drug.

FDA Oncology

@FDAOncology

6 years

Via @aarp : The FDA has recommended expanding certain clinical trials to include older adults. Read why this is important

0

9

7

0

10

34

Harpreet Singh, MD

@harpreet_md

6 months

Great day for patients with EGFR exon 20 ins mut NSCLC! New front line option for high unmet need. 💊

FDA Oncology

@FDAOncology

6 months

FDA approved amivantamab-vmjw for EGFR exon 20 insertion-mutated non-small cell lung cancer indications. #OCENewsBurst #lcsm #nsclc

2

12

28

0

3

35

Harpreet Singh, MD

@harpreet_md

4 years

We wrote about the globalization of #gerionc for the @ASCO Educational Book 📚 👇🏽👇🏽👇🏽

Enrique Soto

@EnriqueSoto8

4 years

Although #ASCO20 #ASCO2020 will not have Ed Sessions, the @ASCO educational book is out with great content. We wrote about the globalization of #gerionc , and of the importance of extending geriatric principles for cancer care to ALL countries! @SIOGorg

5

26

105

1

6

34

Harpreet Singh, MD

@harpreet_md

7 months

Always great to catch up with @JhanelleGray at #TTLC24 @FDAOncology

1

3

31

Harpreet Singh, MD

@harpreet_md

4 months

✨A belated Sto Lat🥳 to Dr. Rick Pazdur, who I’ve had the privilege and honor of working for, and with, for nearly a decade. Visionary leader. Changemaker. Fierce Advocate. Mentor. Confidant. Friend. Thank you for everything ! ✨ @realrickpazdur @FDAOncology

0

31

Harpreet Singh, MD

@harpreet_md

4 years

FDA approves capmatinib for patients with metastatic NSCLC with MET exon 14 skipping #LCSM

FDA Oncology

@FDAOncology

4 years

FDA grants accelerated approval to capmatinib (TABRECTA, Novartis) for metastatic #NSCLC with MET exon 14 skipping. FDA also approved the FoundationOne CDx assay as a companion diagnostic for capmatinib. #LCSM

1

24

49

0

2

30

Harpreet Singh, MD

@harpreet_md

4 years

Proud to be part of OCE. Dr. Pazdur has taught and inspired many, myself included.

FDA Oncology

@FDAOncology

4 years

Congratulations to OCE Director Dr. Richard Pazdur for receiving the Simon M. Shubitz Cancer Prize and Lectureship today from the University of Chicago.

0

8

44

2

31

Harpreet Singh, MD

@harpreet_md

5 months

✨ enjoyed attending #AACR24 with my colleagues and friends ✨ @FDAOncology

1

0

31

Harpreet Singh, MD

@harpreet_md

5 months

Catch up with some of our awesome FDA oncologists here at #AACR24 ✨ @lobo_goulart @jeevanpmd @perevisage @FDAOncology

1

2

31

Harpreet Singh, MD

@harpreet_md

5 years

🧡Happy Diwali 🧡 from ours to yours - ✨wishing you a year rich with wisdom, light, and love ✨

1

0

30

Harpreet Singh, MD

@harpreet_md

6 months

✨Without question, time spent at the @theNCI is a set up for success! As witnessed by this group of leaders and visionaries at FDA and beyond, all with NCI training. Proud to call them colleagues AND friends ✨

0

29

Harpreet Singh, MD

@harpreet_md

10 months

Friends Annual Meeting - Panel 1: Dose Finding in Early Phase Trials💊 #FriendsAM23

0

2

29

Harpreet Singh, MD

@harpreet_md

4 years

Registration link @FDAOncology

0

5

27

Harpreet Singh, MD

@harpreet_md

5 years

Best part of #TTLC20 - hanging with your mentor’s mentor - California strong! @IASLC @drgandara #lcsm

0

2

28

Harpreet Singh, MD

@harpreet_md

2 years

Honored to have served as Faculty for the #WinnCDA BMSF Diversity In Clinical Trials Cohort 2. Such an innovative program, scholars full of promise. Already looking forward to connecting with my cohort and seeing them in person next year! #winncda #bmsf ⁦ @AACR ⁩ ⁦⁩

1

0

28

Harpreet Singh, MD

@harpreet_md

3 years

My experience and career satisfaction at @FDAOncology is driven largely by Dr. Pazdur's leadership, vision, and true dedication to the success of his staff. Worth the read.

ACS Journal Cancer

@JournalCancer

3 years

In this edition of #FirstPerson , we feature Richard Pazdur, MD ( @realrickpazdur ), founding director of the @FDAOncology Center of Excellence, who has long spearheaded major initiatives to improve oncology drug development. Read more about his impact:

0

8

29

0

2

28

Harpreet Singh, MD

@harpreet_md

4 years

It’s a beautiful day in the District

0

27

Harpreet Singh, MD

@harpreet_md

5 years

Spent tonight with the brightest minds in geriatric hematology and oncology. Shared many warm hugs. We are all striving to carry on Arti’s legacy 🙏🏽💗✨ #DrHurriasLight #asco19 @myCARG

Grant R. Williams, MD, MSPH, FASCO

@GrantWilliamsMD

5 years

@rochgerionc leading @myCARG and carrying the torch of #DrHurriasLight at #ASCO19

0

5

19

0

3

27

Harpreet Singh, MD

@harpreet_md

6 years

Of particular relevance in our older adults with cancer who may have organ dysfunction and/or prior malignancies which would otherwise preclude them from enrolling on clinical trials ✨

Gideon Blumenthal

@BlumenthalG

6 years

4 draft guidance documents on expanding eligibility criteria in cancer clinical trials that originated from collaboration between @FDAOncology @ASCO @CancerResrch

0

7

22

0

7

26

Harpreet Singh, MD

@harpreet_md

4 years

@jillfeldman4 I actually made this slide - and yes it has been an amazing year for lung cancer approvals, but more work to be done!

4

2

26

Harpreet Singh, MD

@harpreet_md

5 years

Loves of my life ❤️ today and everyday

0

25

Harpreet Singh, MD

@harpreet_md

4 years

After 20 years, new draft guidance on inclusion of data on older adults in FDA drug labeling. Replaces 2001 guidance! ⬇️⬇️

FDA Oncology

@FDAOncology

4 years

RT @FDAMedia : FDA published draft guidance on geriatric (age 65+) information in prescription drug labeling, to assist drug companies in the placement/content of geriatric information in labeling so it is clear & accessible.

0

1

7

3

12

25

Harpreet Singh, MD

@harpreet_md

3 years

New publication from @NASEM_Health ! Improving the Evidence Base for Treatment Decision Making for Older Adults with Cancer - Proceedings of an @FDAOncology sponsored Workshop in Brief. Available now:

Improving the Evidence Base for Treatment Decision Making for Older Adults with Cancer: Proceedings...

Read online, download a free PDF.

nap.nationalacademies.org

0

9

25

Harpreet Singh, MD

@harpreet_md

4 years

@rochgerionc Thank you. I struggled with the idea of posting. I have so many emotions and it’s so personal for me. I’m heartened by the current movement but we have to keep going.

3

0

25

Harpreet Singh, MD

@harpreet_md

3 months

ASCO 2024 - Rick Pazdur and Adam Feuerstein @adamfeuerstein @statnews

0

1

25

Harpreet Singh, MD

@harpreet_md

5 years

Beverly Canin with my favorite girl. I had the pleasure of hosting her in my home these past few days - we were both on panels at the NCCS event. Remembering Arti as we carry her light forward. I’m sure she’s smiling at this photo✨

4

1

25

Harpreet Singh, MD

@harpreet_md

3 years

Wonderful news for patients and kudos to the @FDAOncology Thoracic Oncology team for expediting this critical approval #LCSM

U.S. FDA

@US_FDA

3 years

Today, FDA approved the first targeted therapy for adult patients with non-small cell lung cancer whose tumors have specific types of genetic mutations.

1

35

78

1

2

25

Harpreet Singh, MD

@harpreet_md

4 months

Honored to bring together so many legends in the thoracic oncology🫁✨

Fred R. Hirsch

@fred_hirsch

4 months

This morning opening of AACR - FDA workshop of treatment of early stage solid cancers. Honored to be a panelist !

0

1

24

0

24

Harpreet Singh, MD

@harpreet_md

4 years

I am honored to serve patients with cancer during these challenging times. Warm wishes and cheers to 2021✨ #OCEWorks4U

FDA Oncology

@FDAOncology

4 years

Happy Holidays and best wishes for the New Year from all of us at the FDA Oncology Center of Excellence.

0

6

41

1

2

25

Harpreet Singh, MD

@harpreet_md

5 years

So immensely proud of my Mother in love (law) for her many accomplishments! She was the 1st black woman to serve as Chief Administrator on Air Force One during the Clinton administration. I know her as my east coast mom, and as a wonderful grandmother ❤️ #BlackHistory

NITRD

@NITRDgov

5 years

We salute #BlackHistoryMonth & #WomensHistoryMonth by recognizing one of our own! Before her service w/ @NITRDgov , @usairforce veteran Virginia Moore was the 1st black woman to serve as the Chief Administrator on Air Force One. We honor her achievements & service to America!

0

1

4

0

1

23

Harpreet Singh, MD

@harpreet_md

5 months

What an amazing tribute to the the great @PamSharmaMDPhD ✨🩺

Jim Allison PhD

@JimAllisonPhD

5 months

Celebrating ⁦ @PamSharmaMDPhD ! Congratulations! Brilliant scientist, compassionate clinician & love of my life. I know I’m a lucky guy.

8

13

268

0

1

22

Harpreet Singh, MD

@harpreet_md

3 years

Had a wonderful time. Thanks for having me! ✨

Stephen V Liu, MD

@StephenVLiu

3 years

Keep you eye out for an upcoming episode of the @IASLC podcast "Lung Cancer Considered", where Dr. @harpreet_md explains what the FDA does and does not do when it comes to approvals! Learn about accelerated vs full approval, how cost factors in, and what an FDA career is like!

0

1

26

0

22

Harpreet Singh, MD

@harpreet_md

5 months

✨No More, No Less✨ Perioperative Pandemonium Trial Designs in Early Stage Solid Tumors @FDAOncology

FDA Oncology

@FDAOncology

5 months

Tomorrow, April 7 at 1 pm PT #AACR24 , join OCE's Dr. Bernardo Goulart @lobo_goulart and Dr. Harpreet Singh @harpreet_md in a panel discussion: No More, No Less: Perioperative Pandemonium: Trial Designs in Solid Tumors. SDCC Upper Level Rm 1. #OCETalks

0

3

0

4

21

Harpreet Singh, MD

@harpreet_md

4 years

So thrilled to welcome Dr. Nieva to this important @FDAOncology event. Proud of my medical home @KeckMedUSC for their work in providing access to quality cancer care across the beautifully diverse LA County. @nievamd @DrElkhoueiry

FDA Oncology

@FDAOncology

4 years

We're pleased to welcome Jorge Javier Nieva, MD @nievamd Associate Professor of Clinical Medicine, USC, to our panel discussion Sept 24, 1-2:30 pm ET, for an OCE Conversation on Cancer, Latino Community 9/24 1-2:30 pm ET. #OCEProjectCommunity Info:

0

1

5

1

5

22

Harpreet Singh, MD

@harpreet_md

1 year

Beautiful Chicago 🤩 let’s go! #ASCO23 @FDAOncology @realrickpazdur

0

22

Harpreet Singh, MD

@harpreet_md

5 years

Dr. Roy Herbst kicking off our @FDAOncology @IASLC @AACR workshop to address the criticality of tobacco use assessment in oncology therapeutic trials! Promises to be an “eye opening” public meeting. #OCETobaccoUse

0

4

22

Harpreet Singh, MD

@harpreet_md

5 years

I say this all the time and believe this wholeheartedly. Thank you for writing this @smlichtman_md

Stuart Lichtman, MD, FASCO

@smlichtman_md

5 years

All Oncologists Are Geriatric Oncologists - The ASCO Post

0

15

37

0

3

21

Harpreet Singh, MD

@harpreet_md

5 years

Twitter is wonderful, but nothing is better than connecting in person! Got to hang out with @NarjustDumaMD today at #TTLC20 - working towards better outcomes for our lung cancer patients! @IASLC #lcsm

1

21

Harpreet Singh, MD

@harpreet_md

5 years

Thanks @HemOncToday for continuing to highlight the need for improving the evidence base for treating older adults with cancer. @myCARG @FDAOncology

HemOnc Today

@HemOncToday

5 years

CDK 4/6 inhibitors effective across age groups in breast cancer subset, according to study by @harpreet_md @US_FDA

0

2

0

6

21

Harpreet Singh, MD

@harpreet_md

4 months

Special intro from Dr. Pazdur, whose visionary leadership continues to move the field forward. #OCEProject5in5 @drjennifergao @DrDonnaRivera

FDA Oncology

@FDAOncology

4 months

What is FDA Oncology's Project 5 in 5? ⏩ OCE Director Dr. Richard Pazdur explains how 𝘆𝗼𝘂 can take part in crowdsourcing to ultimately select 5 clinically relevant questions to be answered in pragmatic clinical trials. #OCEProject5in5

1

18

20

0

1

21

Harpreet Singh, MD

@harpreet_md

5 years

FDA warns about rare but severe lung inflammation with Ibrance, Kisqali, and Verzenio for breast cancer

Rare but severe lung inflammation with certain breast cancer drugs

FDA Drug Safety Communication

www.fda.gov

0

3

21

Harpreet Singh, MD

@harpreet_md

6 years

Great session this morning! Thanks for Arti Hurria and @HKlepinMD and for such active audience participation 🙌🏽✨

Enrique Soto

@EnriqueSoto8

6 years

Packed room for the first #gerionc session at #ASCO18 @ASCO @FDAOncology @HKlepinMD @harpreet_md

1

9

27

0

12

21

Harpreet Singh, MD

@harpreet_md

4 years

@alexdrilon Yes this is a line agnostic approval. Results for 1L and 2L+ shown in section 14 of the label.

1

0

20

Harpreet Singh, MD

@harpreet_md

6 months

Regulating Artificial Intelligence I got to talk to ILCN about what the increasing use of AI means for the Agency as it works to ensure drugs and devices are safe and effective. @FDAOncology @IASLC

Regulating Artificial Intelligence - ILCN.org (ILCN/WCLC)

The US FDA’s Dr. Harpreet Singh talks with ILCN about what the increasing use of AI means for the agency as it works to ensure drugs and devices are safe and effective.

www.ilcn.org

0

2

19

Harpreet Singh, MD

@harpreet_md

5 years

Watching debates tonight - shout out to @amyklobuchar for drawing attention to the “silver surge” in which older adults will dominate our health care system in the coming years. @CARG_Research @myCARG

0

3

20

Harpreet Singh, MD

@harpreet_md

5 months

Registration is now open! ✨ How Much is Enough? Trial Designs for Treatment Regimens with Multiple Phases FDA-AACR ⁦ @FDAOncology ⁩

FDA-AACR Workshop: How Much is Enough? Trial Designs for Treatment Regimens with Multiple Phases

FDA-AACR Workshop: How Much is Enough? Trial Designs for Treatment Regimens with Multiple Phases Date: May 9, 2024 | 9:00 a.m. – 4:00 p.m. Location: The Bethesda Marriott, 5151 Pooks Hill Rd,...

www.aacr.org

0

5

18

Harpreet Singh, MD

@harpreet_md

3 years

Virtual Event: The ASCO Recap, Live! via @statnews @realrickpazdur @pkluetz @FDAOncology

Virtual Event: The ASCO Recap, Live!

STAT's Adam Feuerstein sits down with cancer's biggest decision-maker to discuss his thoughts on the latest trends in cancer drug development.

www.statnews.com

2

3

19

Harpreet Singh, MD

@harpreet_md

6 years

To my colleagues attending ASH, please stop by our poster - Aged Based Analysis of Cytokine Release Syndrome and Neurotoxicity in Patients Treated with CAR-T therapy - presented by Poornima Sharma (not on Twitter) - Monday 12/3 6-8pm Hall GH @FDAOncology @HKlepinMD @tanyawildes

2

9

19

Harpreet Singh, MD

@harpreet_md

4 years

@VivekSubbiah You missed checkmate 9LA regimen approved May 26th!

1

2

19

Harpreet Singh, MD

@harpreet_md

4 years

Thrilled to take part in these discussions - more to come!

FDA Oncology

@FDAOncology

4 years

This week, #FDAOncology held a mini-symposium with leaders from academia and patient advocates to discuss endpoint development for head and neck squamous cell carcinoma. #OCEWorks4U #headandneckcancer #hncsm @hncalliance @vishalbmd @GautamMehtaMD

1

7

29

0

1

19

Harpreet Singh, MD

@harpreet_md

4 years

Concerning data re: exclusion of older adults from clinical trials for COVID-19. It is critical that these trials reflect the populations heavily impacted by COVID. . @sharon_inouye @DrDonaldHarvey @HKlepinMD @rochgerionc @WilliamDale_MD @IshwariaMD

Joseph Abi Jaoude

@JAbiJaoude

4 years

#COVID19 infection in the older population has shown severe morbidity and mortality. Including older patients in clinical trials would generate valid and generalizable results. 4/4

0

1

0

9

19

Harpreet Singh, MD

@harpreet_md

5 years

So excited that Dr. Sharpless is coming to FDA - looking forward to furthering our efforts to improve the evidence base for our older adults with cancer 🤗 @NCIDirector @FDAOncology @myCARG @realrickpazdur

Dr. Kimryn Rathmell

@NCIDirector

5 years

Interesting look at the Cancer and Aging Research Group (CARG) Toxicity Score

2

7

40

0

2

17

Harpreet Singh, MD

@harpreet_md

4 years

Get to know OCE! #OCEWorks4U . @FDAOncology

FDA Oncology

@FDAOncology

4 years

OCE continues to support the cancer community during COVID-19. Meet Dr. Jennifer Gao, Associate Director for Education in the OCE. @drjennifergao #OCEWorks4u

1

2

22

1

5

18

Harpreet Singh, MD

@harpreet_md

4 years

FDA approved durvalumab with chemotherapy for 1L treatment of ES-SCLC 👇🏽

FDA Oncology

@FDAOncology

4 years

FDA has approved durvalumab (IMFINZI, AstraZeneca) in combination with etoposide and either carboplatin or cisplatin as first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC) #lcsm

0

8

15

1

4

18

Harpreet Singh, MD

@harpreet_md

6 months

Thank you for the invitation! That was such a fun talk ! @MedNewsWeek

Yan Leyfman, MD

@YLeyfman

6 months

🌟 Happy International Women's Day! 🌟 Today, we celebrate the remarkable achievements of women in medicine, including our esteemed @MedNewsWeek Keynote Speakers. Your dedication and contributions inspire us all. Thank you for shaping the present & future of healthcare! 🙌

5

10

34

1

5

17

Harpreet Singh, MD

@harpreet_md

4 months

✨Perfect day spending time with colleagues and friends ✨ @FDAOncology

0

1

18